Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 1/20 | 0.43 |
| ▸ | ME1 | P48163 | 1/20 | 0.43 |
| ▸ | ME3 | Q16798 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022710 | 0.84 | MAPT (0.49) | ME2ME1ME3ACHEMAPT | |
| Hydrochloric Acid SCHEMBL6023141 | 0.83 | MAPT (0.48) | ME2ME1ME3ACHEMAPT | |
| SCHEMBL6022488 | 0.82 | MEN1 (0.47) | ME2ME1ME3ACHEGAA | |
| SCHEMBL6022741 | 0.82 | NAMPT (0.43) | ME2ME1ME3ACHEMAPT | |
| SCHEMBL6022736 | 0.82 | NAMPT (0.43) | ME2ME1ME3ACHEMAPT | |
| SCHEMBL6023985 | 0.81 | MEN1 (0.50) | ME2ME1ME3ACHEGAA | |
| SCHEMBL6022708 | 0.81 | MEN1 (0.51) | ME2ME1ME3ACHEGAA | |
| SCHEMBL6023702 | 0.81 | MEN1 (0.51) | ME2ME1ME3ACHEGAA | |
| SCHEMBL6023219 | 0.79 | ME2 (0.52) | ME2ME1ME3ACHEMAPT | |
| SCHEMBL6023942 | 0.78 | ALDH1A1 (0.47) | MAPTKDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | claimed |
| US-7078407-B2 | 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | HTT, PARK7, NQO1 | ME2 635/4885ME1 1938/4885ME3 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.